NCT07155174 RECRUITING A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
AbbVie
NCT04938817 RECRUITING Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Merck Sharp & Dohme LLC
NCT07296809 RECRUITING SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05363280 RECRUITING Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Advenchen Pharmaceuticals, LLC.
NCT07325136 RECRUITING A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
NCT07227597 RECRUITING A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Merck Sharp & Dohme LLC
NCT04553133 ACTIVE NOT RECRUITING PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
NCT07559929 NOT YET RECRUITING A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
NCT04826341 ACTIVE NOT RECRUITING A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Cancer Institute (NCI)
NCT07564401 NOT YET RECRUITING A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Novartis Pharmaceuticals
NCT06503146 RECRUITING 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT07559786 NOT YET RECRUITING A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
Henan Cancer Hospital
NCT05384015 ACTIVE NOT RECRUITING Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
Fundación GECP
NCT05903092 RECRUITING MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Hirva Mamdani
NCT06477523 ACTIVE NOT RECRUITING Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Sichuan University
NCT07551635 NOT YET RECRUITING SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Dana-Farber Cancer Institute
NCT05882058 RECRUITING DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
NCT07339059 RECRUITING Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Bindu R Potugari
NCT07547332 NOT YET RECRUITING Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
Shanghai Pulmonary Hospital, Shanghai, China
NCT07402343 NOT YET RECRUITING Tarlatamab for SCLC Brain Metastases
Maastricht University Medical Center
NCT05617963 ACTIVE NOT RECRUITING Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
UNICANCER
NCT06773910 RECRUITING BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
SCRI Development Innovations, LLC
NCT07476287 RECRUITING Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
NCT02734004 ACTIVE NOT RECRUITING A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
AstraZeneca
NCT07538258 NOT YET RECRUITING Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
Yayi He
NCT07538271 NOT YET RECRUITING A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
Yayi He
NCT06780137 RECRUITING A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Merck Sharp & Dohme LLC
NCT06502977 ACTIVE NOT RECRUITING Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Amgen
NCT05616624 ACTIVE NOT RECRUITING ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
NCT07501169 NOT YET RECRUITING Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sichuan University
NCT07407933 RECRUITING A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07278479 RECRUITING Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
NCT07508852 RECRUITING 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Peking University First Hospital
NCT07055581 RECRUITING Durvalumab as Consolidation for Patients LS-SCLC
Qian Chu
NCT07189871 RECRUITING 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
NCT07480213 RECRUITING Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Beijing Biotech
NCT05142696 ACTIVE NOT RECRUITING A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis Pharmaceuticals
NCT04802174 ACTIVE NOT RECRUITING Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Cancer Institute (NCI)
NCT07001995 NOT YET RECRUITING Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
NCT07472647 NOT YET RECRUITING SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
NCT07465757 NOT YET RECRUITING A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Puma Biotechnology, Inc.
NCT04585750 RECRUITING The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT06681220 RECRUITING Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
VA Office of Research and Development
NCT07391813 RECRUITING SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
SN BioScience
NCT06745323 ACTIVE NOT RECRUITING A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Amgen
NCT06719700 RECRUITING Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
NCT06657222 RECRUITING First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
NCT05546268 ACTIVE NOT RECRUITING Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
NCT06047379 RECRUITING Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT04602533 ACTIVE NOT RECRUITING Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
Michael Hopp
NCT07110103 RECRUITING Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05081609 ACTIVE NOT RECRUITING A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT07425795 RECRUITING Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Chongqing University Cancer Hospital
NCT04644068 ACTIVE NOT RECRUITING Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT07030257 RECRUITING Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07149363 RECRUITING Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
NCT06095505 RECRUITING A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Puma Biotechnology, Inc.
NCT05419076 RECRUITING A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT06943235 RECRUITING Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
Fudan University
NCT07398560 NOT YET RECRUITING Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
NCT06610734 RECRUITING Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Sichuan University
NCT06362252 RECRUITING A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Daiichi Sankyo
NCT05718323 RECRUITING Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
ETOP IBCSG Partners Foundation
NCT07388875 NOT YET RECRUITING Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
China Medical University, China
NCT07381543 NOT YET RECRUITING Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
Peking University Cancer Hospital & Institute
NCT07376499 NOT YET RECRUITING Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
NCT07373964 RECRUITING A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
China Medical University, China
NCT07357532 NOT YET RECRUITING Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
NCT07358676 NOT YET RECRUITING A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07349225 NOT YET RECRUITING Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
The Second Affiliated Hospital of Dalian Medical University
NCT03228667 ACTIVE NOT RECRUITING QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT04686682 RECRUITING A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT05490472 RECRUITING JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT04199741 RECRUITING PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Memorial Sloan Kettering Cancer Center
NCT07321574 RECRUITING A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
NCT07038096 RECRUITING ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05978284 RECRUITING Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04699838 RECRUITING Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Muhammad Furqan
NCT07141264 RECRUITING Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
Tang-Du Hospital
NCT07155200 RECRUITING Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
NCT05060016 ACTIVE NOT RECRUITING A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Amgen
NCT03728361 ACTIVE NOT RECRUITING Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Dwight Owen
NCT07153055 NOT YET RECRUITING Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Misty Shields
NCT05450965 RECRUITING Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
NCT07289048 NOT YET RECRUITING A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT03556228 RECRUITING VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT06758700 RECRUITING Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT07070518 RECRUITING Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT07136285 RECRUITING Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
NCT07253142 NOT YET RECRUITING A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Shanghai Henlius Biotech
NCT07245446 RECRUITING A Study of Ivonescimab in First-Line ES-SCLC
Akeso
NCT07208773 RECRUITING A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06283719 RECRUITING Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT03672773 ACTIVE NOT RECRUITING Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT04397003 ACTIVE NOT RECRUITING Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
NCT05703971 RECRUITING Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Genprex, Inc.
NCT07206563 NOT YET RECRUITING Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT04472949 ACTIVE NOT RECRUITING Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
NCT05924841 RECRUITING A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06838208 RECRUITING Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
NCT05856695 ACTIVE NOT RECRUITING Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
Intergroupe Francophone de Cancerologie Thoracique
NCT05652686 RECRUITING A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
NCT02628067 ACTIVE NOT RECRUITING Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT06812260 ACTIVE NOT RECRUITING A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
NCT07141771 NOT YET RECRUITING An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07109401 RECRUITING Perioperative Immunotherapy for Resectable Limited-Stage SCLC
Fudan University
NCT07097948 NOT YET RECRUITING Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
Shanghai Pulmonary Hospital, Shanghai, China
NCT07091305 ACTIVE NOT RECRUITING A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Shanghai Chest Hospital
NCT07083375 NOT YET RECRUITING A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
Zhijie Wang
NCT07076914 NOT YET RECRUITING Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT07076095 NOT YET RECRUITING A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
NCT03670056 ACTIVE NOT RECRUITING Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
NCT07069270 NOT YET RECRUITING A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
NCT07061535 NOT YET RECRUITING Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03093688 RECRUITING Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Shanghai Public Health Clinical Center
NCT05623319 RECRUITING Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT07022301 NOT YET RECRUITING Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
NCT04952480 RECRUITING Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
AHS Cancer Control Alberta
NCT07004712 NOT YET RECRUITING Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
NCT06429696 RECRUITING PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
NCT04140526 ACTIVE NOT RECRUITING Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4, Inc.
NCT06419179 ENROLLING BY INVITATION Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
University of Cologne
NCT06978153 NOT YET RECRUITING This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer
Tang-Du Hospital
NCT06030258 RECRUITING IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
NCT06914050 NOT YET RECRUITING Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Tianjin Medical University Cancer Institute and Hospital
NCT06483282 RECRUITING A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Jin Ying
NCT06911606 RECRUITING Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
Guangdong Provincial People's Hospital
NCT06909383 NOT YET RECRUITING Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
Guangzhou Institute of Respiratory Disease
NCT04802876 ACTIVE NOT RECRUITING Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06873555 RECRUITING A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Heronova Pharmaceuticals
NCT06663098 RECRUITING Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Gruppo Oncologico Italiano di Ricerca Clinica
NCT05844150 ACTIVE NOT RECRUITING A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Biotheus Inc.
NCT06851819 NOT YET RECRUITING Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
Hebei Medical University Fourth Hospital
NCT04165330 ACTIVE NOT RECRUITING Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
NCT05745350 RECRUITING First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Xiaorong Dong
NCT06820762 NOT YET RECRUITING Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
The Second Affiliated Hospital of Dalian Medical University
NCT06793228 NOT YET RECRUITING Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
Henan Cancer Hospital
NCT06786312 NOT YET RECRUITING A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
NCT06784206 NOT YET RECRUITING Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
NCT06773156 ENROLLING BY INVITATION Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
NCT06771518 RECRUITING Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Regina Elena Cancer Institute
NCT06768307 NOT YET RECRUITING Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
NCT06769971 RECRUITING Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Sichuan University
NCT06749691 RECRUITING Liposomal Irinotecan and Apatinib in ES-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05879068 ACTIVE NOT RECRUITING A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Biotheus Inc.
NCT06739928 RECRUITING Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
NCT06724263 NOT YET RECRUITING A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Tasly Biopharmaceuticals Co., Ltd.
NCT06648200 NOT YET RECRUITING Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT06597513 NOT YET RECRUITING Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
Zhou Chengzhi
NCT06620796 NOT YET RECRUITING A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT06614621 NOT YET RECRUITING A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
NCT06562920 RECRUITING Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Zhejiang Cancer Hospital
NCT06554535 NOT YET RECRUITING Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NCT06479473 RECRUITING Radiotherapy to All Residual Lesions After Chemoimmunotherapy
Anhui Provincial Hospital
NCT06534762 RECRUITING Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
NCT06295926 RECRUITING Serplulimab Combined With CCRT for LS-SCLC.
Peking Union Medical College Hospital
NCT05271292 RECRUITING Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Chipscreen Biosciences, Ltd.
NCT06501976 NOT YET RECRUITING An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06497530 NOT YET RECRUITING Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
NCT04562337 ACTIVE NOT RECRUITING SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Shandong Cancer Hospital and Institute
NCT06485544 RECRUITING Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Tang-Du Hospital
NCT06475209 RECRUITING Adebrelimab + Apatinib in SCLC Maintenance Therapy
Tang-Du Hospital
NCT06371482 RECRUITING Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Hebei Medical University Fourth Hospital
NCT06256237 RECRUITING Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
NCT05443646 RECRUITING Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06243003 RECRUITING WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Fudan University
NCT06236997 NOT YET RECRUITING Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
NCT06177925 RECRUITING A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
NCT06125041 RECRUITING Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
Qianfoshan Hospital
NCT05882630 NOT YET RECRUITING Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
NCT05703997 NOT YET RECRUITING FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT04902872 COMPLETED Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT05337735 SUSPENDED A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
NCT04702880 COMPLETED A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Bristol-Myers Squibb
NCT06897579 TERMINATED Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07328490 WITHDRAWN Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Cancer Institute (NCI)
NCT04660097 COMPLETED Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
NCT04332653 COMPLETED NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT06939036 TERMINATED Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Ariceum Therapeutics GmbH
NCT04418648 TERMINATED Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
Sun Yat-sen University
NCT03575793 COMPLETED A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Salma Sabbour
NCT05001971 COMPLETED Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
NCT04373369 TERMINATED Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
NCT03041311 COMPLETED Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
NCT02514447 COMPLETED Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
NCT04221529 COMPLETED Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
AIO-Studien-gGmbH
NCT06016270 TERMINATED A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
STCube, Inc.
NCT01737502 COMPLETED Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
NCT05509699 COMPLETED Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchison Medipharma Limited
NCT02769832 COMPLETED Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
Muhammad Furqan
NCT02769962 COMPLETED Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04924101 COMPLETED Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Merck Sharp & Dohme LLC
NCT05563272 TERMINATED 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT02611024 COMPLETED Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT04400188 COMPLETED A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT04358237 COMPLETED Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
Antonio Calles Blanco
NCT03554473 COMPLETED M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Cancer Institute (NCI)
NCT04579757 TERMINATED Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
NCT03735095 COMPLETED Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Roswell Park Cancer Institute
NCT02487095 COMPLETED Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Cancer Institute (NCI)
NCT04101357 TERMINATED Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
NCT04209595 COMPLETED PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Cancer Institute (NCI)
NCT05505825 COMPLETED A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
Akeso
NCT04032704 TERMINATED A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
NCT04462276 COMPLETED Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT03997968 COMPLETED A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT03043599 COMPLETED Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02046733 COMPLETED Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
ETOP IBCSG Partners Foundation
NCT04952597 COMPLETED Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
BeiGene
NCT03958045 COMPLETED Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
Zhonglin Hao
NCT03345485 COMPLETED Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Mundipharma Research Limited
NCT03879798 TERMINATED DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT04434482 COMPLETED IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
NCT01904253 TERMINATED A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
NCT00791154 TERMINATED QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
NantCell, Inc.
NCT01357395 COMPLETED A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
Astex Pharmaceuticals, Inc.
NCT04727853 COMPLETED Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
CSPC Ouyi Pharmaceutical Co., Ltd.
NCT04730999 COMPLETED Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica
NCT02978404 COMPLETED Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
NCT02200757 COMPLETED Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
ImmunityBio, Inc.
NCT02937818 COMPLETED A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
NCT05572476 WITHDRAWN Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Institut Bergonié
NCT01941316 COMPLETED Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
NCT04381910 COMPLETED Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
Luye Pharma Group Ltd.
NCT01898156 TERMINATED Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Kyowa Kirin Korea Co., Ltd.
NCT04352413 TERMINATED A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02247349 COMPLETED BMS-986012 in Relapsed/Refractory SCLC
Bristol-Myers Squibb
NCT06052423 WITHDRAWN ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
Hansoh BioMedical R&D Company
NCT04361825 COMPLETED Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
Se-Hoon Lee
NCT03913455 COMPLETED Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Shadia Jalal, MD
NCT02312622 COMPLETED Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Joel Neal
NCT02580994 COMPLETED Pembrolizumab in Untreated Extensive SCLC
European Organisation for Research and Treatment of Cancer - EORTC
NCT05027867 TERMINATED KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Kartos Therapeutics, Inc.
NCT04750239 TERMINATED Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
Y-mAbs Therapeutics
NCT03662074 TERMINATED Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Wake Forest University Health Sciences
NCT04055792 COMPLETED Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
NCT05582031 WITHDRAWN Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Translational Research in Oncology
NCT01642251 COMPLETED Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04590781 TERMINATED Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Xencor, Inc.
NCT03406715 TERMINATED Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
NCT03823118 COMPLETED S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
Taizhou Hospital
NCT02963090 TERMINATED Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
NCT01266018 TERMINATED Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Ludwig Institute for Cancer Research
NCT02359019 COMPLETED MK-3475 as Maintenance Therapy in Extensive Stage SCLC
Barbara Ann Karmanos Cancer Institute
NCT03773133 TERMINATED Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
Ipsen
NCT02945852 COMPLETED Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Fan Yun, MD
NCT04210037 TERMINATED Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
NCT04636762 COMPLETED A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Second Xiangya Hospital of Central South University
NCT03365791 COMPLETED PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis Pharmaceuticals
NCT04841538 WITHDRAWN A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Elpiscience Biopharma, Ltd.
NCT04525391 TERMINATED AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer
Se-Hoon Lee
NCT01935336 COMPLETED Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
NCT00695292 COMPLETED Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
NCT02934503 TERMINATED Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
NCT01631552 COMPLETED Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
NCT02674568 COMPLETED Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
AbbVie
NCT03092934 COMPLETED A Study of AK-01 (LY3295668) in Solid Tumors
Eli Lilly and Company
NCT02701400 COMPLETED Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
Emory University
NCT01573338 TERMINATED Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Bayer
NCT02593019 COMPLETED Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
Samsung Medical Center
NCT02722369 TERMINATED STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
University College, London
NCT03325816 COMPLETED Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Georgetown University
NCT04543916 WITHDRAWN Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Virginia Commonwealth University
NCT03428607 COMPLETED Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
Samsung Medical Center
NCT03009682 COMPLETED Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations
Samsung Medical Center
NCT03059667 COMPLETED Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
NCT00887159 COMPLETED A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
NCT03724253 TERMINATED [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
Advanced Accelerator Applications
NCT01859741 TERMINATED A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
OncoMed Pharmaceuticals, Inc.
NCT02499770 COMPLETED Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
G1 Therapeutics, Inc.
NCT03026166 TERMINATED A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
NCT01803269 TERMINATED Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
NCT02289690 COMPLETED Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
AbbVie
NCT02735980 COMPLETED A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
NCT01876446 COMPLETED Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT01392352 TERMINATED HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT00613626 COMPLETED Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
NCT02551432 COMPLETED Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Seoul National University Hospital
NCT01880528 COMPLETED Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
Mayo Clinic
NCT01797874 COMPLETED Pazopanib Maintenance for SCLC
Samsung Medical Center
NCT02030184 WITHDRAWN Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
NCT02062632 TERMINATED Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
NCT01025284 COMPLETED A Study for Participants With Small-Cell Lung Cancer
Eli Lilly and Company
NCT02109016 TERMINATED A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Clovis Oncology, Inc.
NCT01439568 COMPLETED A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
Eli Lilly and Company
NCT03059797 COMPLETED Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT01253369 COMPLETED Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
NCT01173523 COMPLETED Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
David M. Jackman, MD
NCT02542137 WITHDRAWN Abscopal Effect for Metastatic Small Cell Lung Cancer
Zhejiang Provincial People's Hospital
NCT01722292 TERMINATED A Study of LY2940680 in Small Cell Lung Cancer
Eli Lilly and Company
NCT01497873 COMPLETED A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
NCT02038647 COMPLETED Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Millennium Pharmaceuticals, Inc.
NCT03366675 TERMINATED AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
Samsung Medical Center
NCT02200081 COMPLETED Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Mologen AG
NCT02477813 TERMINATED Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT00702962 TERMINATED Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
NCT03402880 WITHDRAWN ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
NCT03106155 TERMINATED Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification
Samsung Medical Center
NCT02688907 TERMINATED Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
NCT01901653 COMPLETED Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Stemcentrx
NCT00527735 COMPLETED Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
NCT01553916 COMPLETED Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
Washington University School of Medicine
NCT02331251 TERMINATED Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
NCT02748889 TERMINATED Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Giuseppe Giaccone
NCT02161419 TERMINATED RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
Bayer
NCT02261805 TERMINATED A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
NCT01237678 TERMINATED A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
ImmunoGen, Inc.
NCT02876081 WITHDRAWN Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
Fondation Hôpital Saint-Joseph
NCT01441297 COMPLETED BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Ji-youn Han
NCT00828139 COMPLETED S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02425072 WITHDRAWN NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
John Villano
NCT00856830 COMPLETED Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
University of Alabama at Birmingham
NCT01166191 COMPLETED Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)
Maastricht Radiation Oncology
NCT01719861 TERMINATED Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Joel Neal
NCT01640847 WITHDRAWN MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
Imunon
NCT02661100 WITHDRAWN A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
NCT01221675 COMPLETED TF2- Small Cell Lung Cancer Radio Immunotherapy
Centre René Gauducheau
NCT01045421 COMPLETED Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Millennium Pharmaceuticals, Inc.
NCT00682981 COMPLETED A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gemin X
NCT02152059 WITHDRAWN A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
AHS Cancer Control Alberta
NCT02351505 TERMINATED Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
Erin Bertino
NCT01076504 COMPLETED A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
NCT01331525 COMPLETED The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer
University Hospital Southampton NHS Foundation Trust
NCT01533181 COMPLETED Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT01159327 TERMINATED Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
National Cancer Center, Korea
NCT01713296 COMPLETED Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
Hellenic Oncology Research Group
NCT00755157 WITHDRAWN Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
University Hospital of Crete
NCT01421316 TERMINATED Hair-sparing Whole Brain Radiotherapy
University Hospital, Ghent
NCT01500720 COMPLETED Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
NCT00759824 COMPLETED A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
NCT02323737 COMPLETED Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Chinese Academy of Medical Sciences
NCT00912392 COMPLETED Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
NCT00773955 COMPLETED R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00697476 TERMINATED Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
Armando Santoro, MD
NCT00916669 WITHDRAWN A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
Massachusetts General Hospital
NCT00951613 COMPLETED A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
Nippon Kayaku Co., Ltd.
NCT00977561 TERMINATED A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Pfizer
NCT00472771 WITHDRAWN INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
CytRx
NCT01222936 COMPLETED LBH Phase II in Small Cell Lung Cancer (SCLC)
Southern Europe New Drug Organization
